Snapshot from Sep 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Business licensing partnership

Cipla Qilu Keytruda Biosimilar US Deal

Analysis based on 12 articles · First reported Sep 03, 2026 · Last updated Sep 04, 2026

Sentiment
20
Attention
4
Articles
12
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The partnership positions Cipla to enter the lucrative US biosimilar market for Keytruda, potentially capturing significant revenue as the originator faces patent expiry. It also signals growing collaboration between Indian and Chinese pharma firms, which may intensify competition and put downward pressure on oncology drug prices in the US.

Pharmaceuticals Biotechnology

Cipla Ltd, through its wholly owned US subsidiary Cipla — Invagen Pharmaceuticals Inc, has entered into a strategic partnership with China-based Qilu Pharmaceutical for the exclusive licensing and supply of QL2107, a biosimilar to the blockbuster cancer drug Keytruda (pembrolizumab), in the United States. Under the agreement, Qilu will handle development, regulatory registration, and supply, while Cipla will commercialize the product in the US. The deal aims to improve access to advanced cancer therapies and lower treatment costs. This marks Cipla's second licensing pact with a Chinese drugmaker in a week, following its earlier agreement with SK Biopharmaceuticals for a bisimilar antibody-drug conjugate. The partnership reflects Cipla's strategy to build a strong oncology-focused biosimilar portfolio. QL2107 is a biosimilar to pembrolizumab, which is marketed by Merck (MSD) as Keytruda and generated over $31 billion in 2025. As Keytruda approaches its patent cliff, several drugmakers, including Astec LifeSciences with Formycon AG and Abbott Laboratories with Alvogen, are developing biosimilar alternatives. Financial terms of the deal were not disclosed.

100 Cipla partnered with Qilu Pharmaceutical
80 Cipla partnered with SK Biopharmaceuticals
stock
Cipla, through its subsidiary Invagen, is the licensee and commercializer of QL2107 in the US, strengthening its oncology biosimilar portfolio and potential future revenue.
Importance 100.0 Sentiment 20.0
priv
Qilu is the developer and supplier of QL2107, leveraging its R&D and manufacturing strengths to gain US market access through Cipla.
Importance 90.0 Sentiment 20.0
subs
Invagen, Cipla's wholly owned US subsidiary, is the direct party to the licensing agreement and will lead commercialization in the US.
Importance 80.0 Sentiment 20.0
cnt
The US is the target market for QL2107, where regulatory approval and commercialization will occur, impacting US patients and healthcare costs.
Importance 70.0 Sentiment 10.0
stock
Merck markets Keytruda, the originator biologic facing patent cliff; the entry of biosimilars like QL2107 will erode its market share and revenue.
Importance 60.0 Sentiment -10.0
cnt
China is the home of Qilu and SK Biopharmaceuticals, and the partnerships highlight China's increasing influence in pharmaceutical innovation and manufacturing.
Importance 50.0 Sentiment 10.0
cnt
India is the home country of Cipla and several competing firms, and the deal reflects India's growing role in global biosimilar development.
Importance 40.0 Sentiment 10.0
stock
SK Biopharmaceuticals recently partnered with Cipla on a different oncology asset, highlighting Cipla's strategy of in-licensing from Chinese firms.
Importance 40.0 Sentiment 15.0
stock
Zydus is a competitor developing its own Keytruda biosimilar (FYB206) with Formycon AG, facing similar market opportunities.
Importance 30.0 Sentiment 10.0
stock
Dr. Reddy's is another Indian competitor developing a Keytruda biosimilar with Alvogen, targeting the same US market.
Importance 30.0 Sentiment 10.0
per
Achin Gupta, Cipla's MD and Global CEO, publicly endorsed the partnership, reflecting strategic commitment to biosimilars.
Importance 30.0 Sentiment 10.0
stock
Formycon AG is Zydus's partner in developing a Keytruda biosimilar, competing in the same emerging market.
Importance 20.0 Sentiment 10.0
priv
Alvogen is Dr. Reddy's partner in developing a Keytruda biosimilar, competing in the biosimilar space.
Importance 20.0 Sentiment 10.0
per
Marc Falkin, CEO of Cipla North America, highlighted the company's commercial readiness to launch QL2107 upon approval.
Importance 20.0 Sentiment 10.0
per
Zhang Ping, General Manager of Qilu, expressed confidence in the partnership to bring an affordable biosimilar to US patients.
Importance 20.0 Sentiment 10.0
Cipla related ↔ India
United States strategic rival ↔ China The United States perceives China as a strategic rival, actively implementing sanctions and export controls, while addre
United States strategic partners ↔ India The United States considers India a vital strategic and economic partner, actively pursuing defense and trade agreements
Merck Group related ↔ China
Merck Group related ↔ India
China strategic rivals ↔ India China views India as a significant strategic and economic competitor with whom it has unresolved territorial and trade d
Astec LifeSciences no relationship ↔ Abbott Laboratories Astec LifeSciences and Abbott Laboratories do not have a direct business-to-business relationship. Astec LifeSciences is
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.